Therapeutic Efficacy of Piperazine Ferulate Combined With Irbesartan in Diabetic Nephropathy: A Systematic Review and Meta-analysis

Abstract

Purpose: Irbesartan is widely used clinically in the treatment of diabetic nephropathy (DN). It is believed that piperazine ferulate (PF) combined with irbesartan could result in an improved efficacy in the treatment of DN. We present the latest meta-analysis that details the combination of PF and irbesartan therapy. Methods: Before January 31, 2020, we searched various electronic databases for appropriate articles. Our search was not restricted by keyword or language. We then filtered all articles using certain criteria and assessed the quality of the qualified studies. Findings: The meta-analysis included 12 trials that involved 1300 patients (650 in the experimental group and 650 in the control group). The ages of the patients ranged from 30 to 79 years. Compared with irbesartan alone, the total effective rate of PF combined with irbesartan was significantly higher (odds ratio [OR] ¼ 4.95; 95% CI, 3.11e7.58; P < 0.0001). The blood glucose level was controlled by significantly decreasing the fasting plasma glucose level (mean difference [MD] ¼ −1.40; 95% CI, −2.70 to −0.11; P ¼ 0.03) and 2-h plasma glucose level (MD ¼ −1.65; 95% CI, −2.49 to −0.82; P < 0.0001). The combination therapy significantly decreased the levels of serum creatinine (MD ¼ −10.24; 95% CI, −15.25 to −5.23; P < 0.0001), 24-h urinary protein (MD ¼ −0.

Piperazine ferulate prevents high‑glucose‑induced filtration barrier injury of glomerular endothelial cells

“…of DN (17). Our previous study also demonstrated that PF retarded the progression of DN (16) and attenuated the high glucose (HG)-induced mesangial cell injury (18).…”

“…1A ) is a derivative of ferulic acid that exhibits anti-hypertensive effects ( 14 ), reduces IgA-mediated nephropathy ( 15 ) and prevents the development of DN ( 16 ). A systematic meta-analysis indicated that PF combined with irbesartan could improve the efficiency of treatment of DN ( 17 ). Our previous study also demonstrated that PF retarded the progression of DN ( 16 ) and attenuated the high glucose (HG)-induced mesangial cell injury ( 18 ).…”

Ophiocordyceps sinensis preparations combined with the renin–angiotensin system inhibitor for diabetic kidney disease treatment: an umbrella review of systematic reviews and network meta-analysis

“…We conducted an additional search of 264 RCTs. After 397 overlapping RCTs were excluded and further screened according to the eligibility criteria, a total of 157 eligible RCTs were included in the final analysis ( Jia, 1999 ; Cao et al, 2007 ; Chen, 2007 ; Chen, 2009 ; Cui et al, 2009 ; Lei et al, 2009 ; Li and Liu, 2009 ; Chen et al, 2010 ; Guan et al, 2010 ; Hong, 2010 ; Huang et al, 2010 ; Chen, 2011 ; Cao, 2012 ; He and Lu, 2012 ; Hu and Wei, 2012 ; Gao and Wei, 2013 ; Ding, 2014 ; Cao, 2015 ; Diao, 2015 ; Chen et al, 2016 ; Dai, 2016 ; Hu, 2016 ; Huang and Zhou, 2016 ; Jin, 2016 ; Chen, 2017 ; Feng, 2017 ; He, 2017 ; Hou et al, 2017 ; Lei et al, 2017 ; Gao, 2018 ; Hu et al, 2018 ; Dai, 2019 ; Hu, 2019 ; Cheng, 2021 ; Du, 2021 ; Guan et al, 2021 ; Han, 2021 ; Jiang, 2021 ; Ding et al, 2022 ; Dong, 2022 ; Huang et al, 2022 ; Li and Lv, 2011 ; Li et al, 2019 ; Li, 2012 ; Li, 2010 ; Li, 2012 ; Li, 2017 ; Li, 2019 ; Li, 2023 ; Lin, 2009 ; Lin, 2016 ; Liu and Jian, 2020 ; Liu and Li, 2011a ; Liu and Li, 2011b ; Liu and Zhang, 2017 ; Liu et al, 2016a ; Liu et al, 2016b ; Liu, 2010 ; Li...…”

Gentiopicroside Ameliorates Diabetic Renal Tubulointerstitial Fibrosis via Inhibiting the AT1R/CK2/NF-κB Pathway

“…Physically, creatinine is cleared away from plasma by glomerular filtration and then excreted into the urine without tubular reabsorption. Therefore, the amount of Scr is constant under normal conditions, and an increased Scr level usually indicates the impaired renal function ( Li et al, 2020 ). In addition to that, urea nitrogen, the main end product of protein metabolism, is another important parameter to evaluate the renal function.…”